SGEN:NSD-Seattle Genetics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 184.95

Change

0.00 (0.00)%

Market Cap

USD 32.18B

Volume

0.86M

Average Target Price

USD 164.34 (-11.14%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seattle Genetics, Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; biotechnology and pharmaceutical companies; and Merck. Seattle Genetics, Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. Address: 21823 30th Drive SE, Bothell, WA, United States, 98021

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

N/A

USD61.08B 21.61 16.69
MRNA Moderna, Inc

N/A

USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

N/A

USD24.87B N/A N/A
RPRX Royalty Pharma plc

N/A

USD24.33B 36.15 9.83
GMAB Genmab A/S

N/A

USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

N/A

USD19.73B N/A N/A
INCY Incyte Corporation

N/A

USD18.93B 47.64 35.20
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD16.04B N/A N/A

ETFs Containing SGEN

Symbol Name Weight Mer Price(Change) Market Cap
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD0.21B
AGES:LSE iShares Ageing Population.. 0.00 % 0.40 %

N/A

USD0.28B
2B77:XETRA iShares Ageing Population.. 0.00 % 0.40 %

N/A

USD0.28B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
ITEK:LSE HAN-GINS Innovative Techn.. 0.00 % 0.75 %

N/A

USD5.53M
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.40 %

N/A

USD0.51B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.40 %

N/A

USD0.47B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.26B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.26B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.07B
AGED:LSE iShares Ageing Population.. 0.00 % 0.40 %

N/A

USD0.28B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD0.01B
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

N/A

USD0.15B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

N/A

USD0.03B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

N/A

USD0.10B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

N/A

USD0.46B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.47 %

N/A

USD9.52B
FHH:CA FT AlphaDEX U.S. Health C.. 0.00 % 0.70 %

N/A

USD0.01B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.40 %

N/A

USD1.35B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 61.87% 82% B- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.87% 82% B- 88% B+
Trailing 12 Months  
Capital Gain 143.36% 86% B 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 143.36% 86% B 92% A-
Trailing 5 Years  
Capital Gain 396.11% 92% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 396.11% 92% A- 94% A
Average Annual (5 Year Horizon)  
Capital Gain 40.91% N/A N/A 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.91% N/A N/A 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 45.41% N/A N/A 26% F
Risk Adjusted Return 90.09% N/A N/A 90% A-
Market Capitalization 32.18B 100% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 17.21 7% F 7% F
Price / Cash Flow Ratio -196.54 99% A+ 98% A+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -16.57% 88% B+ 38% F
Return on Invested Capital -14.00% 85% B 31% F
Return on Assets -11.20% 84% B 26% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.90 45% F 34% F
Short Percent 6.89% 47% F 31% F
Beta 1.26 62% D- 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.